<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-541
Date of Submission: 2025-02-24

This report was submitted by a Nurse from Oneill Inc Medical Center concerning patient ANON-PX-7580. The subject is a 84-year-old other with a significant medical history including migraines, osteoarthritis, atrial fibrillation, type 2 diabetes. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Ibuprofen (NSAID) administered via the Oral route at a dosage of 51mg, initiated on 2024-12-17 for Pain and inflammation and discontinued on 2025-02-02; Omeprazole administered via the Intramuscular route at a dosage of 403mg, initiated on 2024-12-17 for Gastroesophageal reflux disease and discontinued on 2025-02-02.

On approximately 2025-01-02, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Hepatotoxicity. The Angioedema was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Recovered'. The Hepatotoxicity was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Impact see near use. Report hard present system brother.</data>
report_id: ADR-2025-541
report_date: '2025-02-24'
patient_details:
  patient_id: ANON-PX-7580
  gender: Other
  relevant_history:
  - migraines
  - osteoarthritis
  - atrial fibrillation
  - type 2 diabetes
  age_at_reaction: 84
suspected_drugs:
- drug_name: Ibuprofen
  dosage: 51mg
  route_of_administration: Oral
  start_date: '2024-12-17'
  indication_for_use: Pain and inflammation
  drug_class: NSAID
  end_date: '2025-02-02'
- drug_name: Omeprazole
  dosage: 403mg
  route_of_administration: Intramuscular
  start_date: '2024-12-17'
  indication_for_use: Gastroesophageal reflux disease
  end_date: '2025-02-02'
adverse_reactions:
- symptom_name: Angioedema
  onset_date: '2025-01-02'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: true
- symptom_name: Hepatotoxicity
  onset_date: '2025-01-02'
  severity: Moderate
  outcome: Unknown
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
reporting_facility: Oneill Inc Medical Center
reporter_type: Nurse
notes: Impact see near use. Report hard present system brother.
